PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 5, 2026Cancer Research

Abstract 5380: Prognostic utility of minimal residual disease detection using circulating tumor DNA in early-stage breast cancer: A systematic review and meta-analysis.

View Full Paper
Ask AI
Bookmark
Share

Authors

PEPanuch EiamprapapornTSThiti SusiriwatananontYMY. Ma

Discussion

Loading...

Member takes

Overview

Systematic review reveals ctDNA detection predicts disease recurrence in early-stage breast cancer, suggesting tailored interventions.

Key Points

  • To evaluate the prognostic utility of ctDNA-based minimal residual disease detection in early-stage breast cancer.
  • Conducted a systematic review and meta-analysis using data from multiple databases.
  • Included studies on early-stage breast cancer patients with ctDNA-based MRD detection and ≥12 months follow-up.
  • Assessed pooled hazard ratio for disease recurrence through random-effects meta-analysis.
  • Meta-analysis showed a pooled hazard ratio of 9.95 indicating high recurrence risk in ctDNA-positive patients.
  • TNBC had the highest detection and sensitivity rates, while HR+/HER2- showed the lowest.
  • Detected cases of recurrence provided a median lead time of 10.2 months before clinical symptoms.

Cite This Study

Eiamprapaporn et al. (2026) studied this question.

synapsesocial.com/papers/69d1fd4ea79560c99a0a3366https://doi.org/10.1158/1538-7445.am2026-5380
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract PS06-06: Analysis of ctDNA for the detection of minimal residual disease (MRD) using a tissue-free, multiomic assay in patients with early-stage breast cancer2024 · 7 citations
  2. 2Abstract 7849: Real-world landscape analysis of circulating tumor DNA minimal residual disease as a clinical trial endpoint in breast cancer.2026
  3. 3Abstract PS2-10-19: Circulating tumor DNA (ctDNA) as a strong prognostic biomarker of minimal residual disease (MRD) using a tissue-free, epigenomic assay in early-stage breast cancer2026
  4. 4Abstract PS2-10-20: Dual biomarker approach for minimal residual disease detection in early breast cancer using high-volume blood samples2026
  5. 5Abstract 2420: Evaluating circulating tumor DNA (ctDNA) as a prognostic biomarker utilizing a tissue-free epigenomic assay in early-stage triple negative breast cancer (TNBC)2024